The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: A cause for optimism

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 1, 2015, Pages 2-8

  Rigas, Basil ^a   Tsioulias, George J ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENZYLAMINE DERIVATIVE; CELECOXIB; EFLORNITHINE; ETODOLAC; IBUPROFEN DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PHOSPHATIDYLCHOLINE; ROFECOXIB; SULINDAC; WARFARIN;

ABERRANT CRYPT FOCUS; AMIDATION; CANCER PREVENTION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; COLON POLYP; COLORECTAL CANCER; COLORECTAL POLYP; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ESTERIFICATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; THROMBOCYTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; COLORECTAL NEOPLASMS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; HUMANS;

EID: 84923363067     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220806     Document Type: Review

References (87)

1. Al-Kharusi MR, Smartt HJ, Greenhough A, Collard TJ, Emery ED, Williams AC, and Paraskeva C (2013) LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis 34:1150-1157.
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899.
3. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, and Chaussade S (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328-336.
4. Bezawada N, Song M, Wu K, Mehta RS, Milne GL, Ogino S, Fuchs CS, Giovannucci EL, and Chan AT (2014) Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res (Phila) 7:758-765.
5. Bosetti C, Rosato V, Gallus S, Cuzick J, and La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23:1403-1415.
6. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, et al.; International CAPP consortium (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4:655-665.
7. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, et al.; CAPP2 Investigators (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081-2087.
8. Burt RW, DiSario JA, and Cannon-Albright L (1995) Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 46:371-379.
9. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, and Baron JA (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 5:164-178.
10. Chan TY (1995) Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 29:1274-1283.
11. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, and Tappenden P (2010) Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 14:1-206.
12. Delaney JA, Opatrny L, Brophy JM, and Suissa S (2007) Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177:347-351.
13. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, and Moher D; U. S. Preventive Services Task Force (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 146:365-375.
14. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, et al. (2014) Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl 6:233-232.
15. Garcia-Albeniz X and Chan AT (2011) Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 25:461-472.
16. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316.
17. Gill S and Sinicrope FA (2005) Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol 32:24-34.
18. Haanen C (2001) Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs 2:677-683.
19. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, and Arber N (2003) Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998-2002.
20. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, and Rigas B (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52:237-245.
21. Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, and Rigas B (2011) Chemotherapeutic properties of phospho-nonsteroidal antiinflammatory drugs, a new class of anticancer compounds. Cancer Res 71:7617-7627.
22. Iguchi G, Chrysovergis K, Lee SH, Baek SJ, Langenbach R, and Eling TE (2009) A reciprocal relationship exists between non-steroidal anti-inflammatory drugactivated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett 282:152-158.
23. Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, et al. (2014) The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63:1755-1759.
24. Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, et al. (2013) Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2:50-56.
25. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, and Marnett LJ (2000) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 97:925-930.
26. Kalgutkar AS, Crews BC, Saleh S, Prudhomme D, and Marnett LJ (2005) Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg Med Chem 13:6810-6822.
27. Kaminski R, Kozicka M, Parada-turska J, Dziki M, Kleinrok Z, Turski WA, and Czuczwar SJ (1998) Effect of non-steroidal anti-inflammatory drugs on the anticonvulsive activity of valproate and diphenylhydantoin against maximal electroshock-induced seizures in mice. Pharmacol Res 37:375-381.
28. Kashfi K and Rigas B (2005) Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 33:724-727.
29. Kim TI (2014) Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J Gastroenterol 20:3835-3846.
30. Klabunde CN, Cronin KA, Breen N, Waldron WR, Ambs AH, and Nadel MR (2011) Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 20:1611-1621.
31. Kune GA, Kune S, and Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399-4404.
32. Laukaitis CM and Gerner EW (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506.
33. Lichtenberger L, Waters D, Phan T, and Dial E (2014) GI-safe NSAIDs and the suppression of colon cancer. FASEB J 26:840-845.
34. Lim YJ, Dial EJ, and Lichtenberger LM (2013) Advent of novel phosphatidylcholineassociated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety. Gut Liver 7:7-15.
35. Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, and Ogino S (2014) Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 109:1205-1214.
36. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, and Muir KR; ukCAP Trial Group (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29-38.
37. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, and Boland CR (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535-1549.
38. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, and Rigas B (2011) Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 4:1052-1060.
39. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, and Rigas B (2010) Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139:1320-1332.
40. Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, et al. (2014) Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147:784-792.e9.
41. Mattheolabakis G, Wong CC, Sun Y, Amella CA, Richards R, Constantinides PP, and Rigas B (2014) Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. J Pharmacol Exp Ther 351:61-66.
42. Meyskens FL, Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32-38.
43. Miner J and Hoffhines A (2007) The discovery of aspirin's antithrombotic effects. Tex Heart Inst J 34:179-186.
44. Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI, and Kim WH (2014) Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer 134:519-529.
45. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, et al. (2013) Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369:1095-1105.
46. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, and Ogretmen B (2010) Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6:1603-1624.
47. Ponz de Leon M, Sassatelli R, Benatti P, and Roncucci L (1993) Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer 71:3493-3501.
48. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, and Rigas B (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258:215-223.
49. Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H, Oue N, Yasui W, Clevers H, Schoen RE, et al. (2010) Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA 107:20027-20032.
50. Rasheed S and Rigas B (2008) Screening for colorectal cancer: does it all start with aberrant crypt foci? Gastrointest Endosc 67:1103-1105.
51. Rigas B (2007a) Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans 35:1364-1368.
52. Rigas B (2007b) The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 23:55-59.
53. Rigas B and Sun Y (2008) Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 98:1157-1160.
54. Rigas B and Williams JL (2008) NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19:199-204.
55. Rigas B, Goldman IS, and Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518-523.
56. Roderick PJ, Wilkes HC, and Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35:219-226.
57. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, and Moher D; U. S. Preventive Services Task Force (2007) Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 146:376-389.
58. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, and Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41.
59. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-1612.
60. Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, and Pariente A; Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project (2011) Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 89:855-866.
61. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890.
62. Schrör K (2011) Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 25:473-484.
63. Serebruany VL, Malinin AI, Eisert RM, and Sane DC (2004) Risk of bleeding complications with antiplatelet agents: meta-analysis of 338, 191 patients enrolled in 50 randomized controlled trials. Am J Hematol 75:40-47.
64. Shiff SJ, Koutsos MI, Qiao L, and Rigas B (1996) Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222:179-188.
65. Shiff SJ and Rigas B (1999a) Aspirin for cancer. Nat Med 5:1348-1349.
66. Shiff SJ and Rigas B (1999b) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190:445-450.
67. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, et al.; APC and PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028-1035.
68. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
69. Stolfi C, De Simone V, Pallone F, and Monteleone G (2013) Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci 14:17972-17985.
70. Sun Y and Rigas B (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68:8269-8277.
71. Sun Y, Chen J, and Rigas B (2009) Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 30:93-100.
72. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, and Niitsu Y (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339:1277-1284.
73. Takayama T, Miyanishi K, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Kogawa T, Abe T, and Niitsu Y (2005) Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness. Clin Gastroenterol Hepatol 3:S42-S45.
74. Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M, et al. (2011) Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clinl Cancer Res 17:3803-3811.
75. Tárraga Löpez PJ, Albero JS, and Rodríguez-Montes JA (2014) Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol 7:33-46.
76. Thun MJ and Blackard B (2009) Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of aspirin to prevent cancer. Recent Results Cancer Res 181:215-221.
77. Tinsley HN and Piazza GA (2012) Novel therapeutics: NSAIDs, derivatives, and phosphodiesterases. Curr Colorectal Cancer Rep 8:325-330.
78. Verbeeck RK (1990) Pharmacokinetic drug interactions with nonsteroidal antiinflammatory drugs. Clin Pharmacokinet 19:44-66.
79. Wang X, Kingsley PJ, Marnett LJ, and Eling TE (2011) The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac. Cancer Prev Res (Phila) 4:150-160.
80. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, et al. (2012) A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prev Res (Phila) 5:822-833.
81. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, and Rigas B (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC (Min/+)) mice. Biochem Biophys Res Commun 313:784-788.
82. Wong CC, Cheng KW, and Rigas B (2012a) Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther 341:572-578.
83. Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, and Rigas B (2012b) Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal antiinflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340:422-432.
84. Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, and Rigas B (2011) Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337:876-886.
85. Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, et al. (2012a) The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol 165:2152-2166.
86. Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, and Rigas B (2012b) Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety. Br J Pharmacol 167:222-232.
87. Zhou D, Papayannis I, Mackenzie GG, Alston N, Ouyang N, Huang L, Nie T, Wong CC, and Rigas B (2013) The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis 34:943-951.